Core Viewpoint - MicroPort Scientific Corporation-B (02252) reported a significant increase in revenue and a reduction in net losses for the six months ending June 30, 2025, leading to a stock price increase of over 6% following the earnings announcement [1] Financial Performance - The company achieved a revenue of 176 million yuan, representing a year-on-year increase of 77% [1] - Adjusted net loss for the period was 97.1 million yuan, a decrease of 55.5% compared to the previous year [1] - Loss attributable to equity shareholders was 113 million yuan, down 59.1% year-on-year [1] - Earnings per share reported a loss of 0.11 yuan [1] Revenue Growth Drivers - Revenue growth was primarily driven by the rapid commercialization of multiple products, with overseas market revenue increasing by 189% year-on-year [1] - The core product, the TiMARS surgical robot, continued to show strong growth, particularly in overseas markets, which became the main engine for revenue growth [1] - The Honghu orthopedic surgical robot leveraged MicroPort's established sales network to achieve rapid coverage and penetration in key regions, while also expanding into emerging areas, creating a "dual-drive" model for steady growth [1] - The R-ONE vascular interventional surgical robot gained market recognition post-launch, with steadily increasing demand [1]